Rhythm Biosciences closer to cancer detection breakthrough

Written by Justin Ware, edited and authorised by Jonathan Jackson. Published at Apr 24, 2018, in Biotech

Rhythm Biosciences (ASX:RHY) has provided an important update on its reagent development program.

The program is of significant importance to the company’s ColoSTATTM antibody-based blood test for the early detection of colorectal cancer.

RHY has indicated that the program has showcased positive progress to date and remains on schedule.

Under a research contract with the CSIRO, five mixed monoclonal antibody preparations have passed two out of three preliminary screening tests with the final stage of screening now in progress.

Completion of these tests triggers cloning of the cells required to produce antibodies of interest for ColoSTAT­TM . ­Additional tests will be performed to identify which antibodies are best suited to the diagnostic purpose of ColoSTAT­TM.

Once these are identified, the antibody-producing cell lines will join those already in hand for the two target biomarkers Rhythm has secured. This will lead to the optimisation of antibody production and purification at a laboratory scale, which will support the development of scalable antibody protocols for production of these reagents by a contract manufacturer.

As always, it should be noted that RHY is an early stage play and anything can happen, so seek professional financial advice if considering this stock for your portfolio.

ColoSTAT­TM uses antibodies to measure the levels of several proteins in the blood. The concentrations of these proteins in blood have been shown to vary in the presence or absence of colorectal cancer.

RHY Managing Director Trevor Lockett spoke on the development.

“Rhythm’s objective in the coming months is to develop our own antibodies and target proteins to give us control of the supply, quality and cost of these key reagents.

“The positive progress to date is essential in underpinning the reliable manufacture of test kits with consistently high diagnostic performance properties, and the results we have achieved in pursuit of this to date have been very pleasing.”

S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of Maven Capital Pty Ltd (AFSL No. 418504). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.

Conflict of Interest Notice

S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.

Publishers Notice

The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.

Facebook
Twitter
LinkedIn